^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

UD TGFbetai NK cells

i
Other names: UD TGFbetai NK cells
Associations
Company:
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James)
Drug class:
NK cell stimulant
Related drugs:
Associations
10ms
Enrollment open • Immune cell
|
cyclophosphamide • Sarclisa (isatuximab-irfc) • Hemady (dexamethasone tablets) • UD TGFbetai NK cells
10ms
New P1 trial • Immune cell
|
cyclophosphamide • Sarclisa (isatuximab-irfc) • Hemady (dexamethasone tablets) • UD TGFbetai NK cells
11ms
Phase classification
|
HER-2 (Human epidermal growth factor receptor 2) • CD4 (CD4 Molecule)
|
HER-2 negative
|
gemcitabine • Danyelza (naxitamab-gqgk) • UD TGFbetai NK cells
11ms
New P1/2 trial
|
HER-2 (Human epidermal growth factor receptor 2) • CD4 (CD4 Molecule)
|
HER-2 negative
|
gemcitabine • Danyelza (naxitamab-gqgk) • UD TGFbetai NK cells
1year
Enrollment open • Tumor mutational burden • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • CD4 (CD4 Molecule) • TGFBI (Transforming Growth Factor Beta Induced)
|
HER-2 negative
|
gemcitabine • Danyelza (naxitamab-gqgk) • UD TGFbetai NK cells
almost2years
Enrollment open • Preclinical • Combination therapy • Metastases
|
TGFB1 (Transforming Growth Factor Beta 1)
|
temozolomide • UD TGFbetai NK cells
2years
New P1/2 trial • Preclinical • Combination therapy • Metastases
|
TGFB1 (Transforming Growth Factor Beta 1)
|
temozolomide • UD TGFbetai NK cells